New Technology Transfer Boosts Affordable Cancer and Infection Treatments in India
Delhi, 21 July – In a landmark move, ICMR has handed over three indigenous biomedical technologies to top Indian pharmaceutical and vaccine firms for commercial exploitation. The decision is described as a major step in turning publicly funded research into cost‑effective health services. The partnership includes the licensing of “Sheta‑2”, an HPV‑targeted drug aimed at cervical intra‑epithelial neoplasia, to Mkure Pharmaceuticals Ltd. The drug was created by Dr. Shaquat Hussain of ICMR‑NICPR in collaboration with Dr. Doris M. Benbrook of the University of Oklahoma. It works by pinpointing and destroying HPV‑positive cervical cells without damaging healthy tissue, potentially reducing the need for extensive surgery. Two advanced vaccine platforms designed at ICMR‑NIRBI, Kolkata, to protect against gut‑origin bacterial infections have been assigned to Biological E Ltd. One platform uses a fusion of Salmonella typhi’s outer‑membrane protein, promising a next‑generation typhoid vaccine. The other is a recombinant vaccine that offers broad protection against S. typhi, S. paratyphi and Shigella. The Ministry of Health stresses that these technology transfers will reinforce national efforts toward cancer prevention and infectious disease control, while also nurturing a self‑reliant pipeline of future medicines and immunisations.